bexarotene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
arotinoid derivatives	361	153559-49-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

LGD 1069
bexarotene
targretin
targretyn
targrexin

A tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA.

Molecular weight: 348.49
Formula: C24H28O2
CLOGP: 8.19
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -6.37
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.01 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	28.70 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
March 29, 2001	EMA
Dec. 29, 1999	FDA	VALEANT LUXEMBOURG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertriglyceridaemia	89.88	41.92	18	406	5473	50599227
Cutaneous T-cell lymphoma	51.81	41.92	9	415	1255	50603445

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypothyroidism	123.22	29.35	36	795	15870	29557826
Hypertriglyceridaemia	104.77	29.35	27	804	7448	29566248
Cutaneous T-cell lymphoma	75.52	29.35	15	816	1278	29572418
Dyslipidaemia	39.32	29.35	12	819	6049	29567647
Thyroid stimulating hormone deficiency	32.92	29.35	4	827	10	29573686

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertriglyceridaemia	168.95	29.17	40	1227	11165	64486300
Hypothyroidism	142.30	29.17	46	1221	40411	64457054
Cutaneous T-cell lymphoma	126.34	29.17	24	1243	2328	64495137
Dyslipidaemia	47.09	29.17	14	1253	9228	64488237
Diffuse large B-cell lymphoma	45.51	29.17	14	1253	10347	64487118
Blood triglycerides increased	40.97	29.17	15	1252	18851	64478614
Thyroid stimulating hormone deficiency	34.35	29.17	4	1263	10	64497455
Skin exfoliation	31.35	29.17	16	1251	44869	64452596

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XF03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment
FDA CS	M0018962	Retinoids
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000175607	Retinoid
CHEBI has role	CHEBI:35610	antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Primary cutaneous T-cell lymphoma	indication	400122007
Alcoholism	contraindication	7200002
Hypothyroidism	contraindication	40930008	DOID:1459
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Leukopenia	contraindication	84828003	DOID:615
Bilateral cataracts	contraindication	95722004
Disorder of biliary tract	contraindication	105997008	DOID:9741
Acute pancreatitis	contraindication	197456007	DOID:2913
Chronic pancreatitis	contraindication	235494005
Disease of liver	contraindication	235856003	DOID:409
Diabetic - poor control	contraindication	268519009
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.23	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1%	BEXAROTENE	AMNEAL	A215398	April 27, 2022	RX	GEL	TOPICAL	Nov. 13, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Retinoic acid receptor RXR-beta	Nuclear hormone receptor	P28702	RXRB_HUMAN	AGONIST	Ki	8.23		CHEMBL	CHEMBL
Retinoic acid receptor RXR-gamma	Nuclear hormone receptor	P48443	RXRG_HUMAN	AGONIST	Ki	8.08		CHEMBL	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN	AGONIST	Kd	7.85		CHEMBL	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN		Ki	6.89		CHEMBL
Cytochrome P450 26A1	Enzyme	O43174	CP26A_HUMAN		IC50	4.87		CHEMBL
Cytochrome P450 26B1	Enzyme	Q9NR63	CP26B_HUMAN		IC50	5.23		CHEMBL
Oxysterols receptor LXR-beta	Nuclear other	P55055	NR1H2_HUMAN		EC50	6.36		CHEMBL
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN		Ki	6.74		CHEMBL
Oxysterols receptor LXR-alpha	Nuclear other	Q13133	NR1H3_HUMAN		EC50	6.71		CHEMBL
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN	ANTAGONIST	IC50	5.52		IUPHAR
Retinoic acid receptor beta	Nuclear hormone receptor	P10826	RARB_HUMAN		Ki	7.30		CHEMBL
Retinoic acid receptor RXR-beta	Transcription factor		RXRB_MOUSE		Kd	7.68		CHEMBL
Retinoic acid receptor RXR-gamma	Transcription factor		RXRG_MOUSE		Kd	7.54		CHEMBL
Retinoic acid receptor RXR-alpha	Transcription factor		RXRA_MOUSE		EC50	7.40		CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor		RXRA_RAT		EC50	7.40		CHEMBL

External reference:

ID	Source
4021197	VUID
N0000148643	NUI
D03106	KEGG_DRUG
233272	RXNORM
C0765273	UMLSCUI
CHEBI:50859	CHEBI
9RA	PDB_CHEM_ID
CHEMBL1023	ChEMBL_ID
DB00307	DRUGBANK_ID
D000077610	MESH_DESCRIPTOR_UI
82146	PUBCHEM_CID
2807	IUPHAR_LIGAND_ID
7782	INN_ID
A61RXM4375	UNII
234760	MMSL
31640	MMSL
8604	MMSL
d04507	MMSL
008004	NDDF
116346006	SNOMEDCT_US
387023000	SNOMEDCT_US
4021197	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0399	CAPSULE, LIQUID FILLED	75 mg	ORAL	ANDA	25 sections
Targretin	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5525	GEL	1 g	TOPICAL	NDA	20 sections
Targretin	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5525	GEL	1 g	TOPICAL	NDA	20 sections
Targretin	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5526	CAPSULE, LIQUID FILLED	75 mg	ORAL	NDA	25 sections
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6955	CAPSULE, LIQUID FILLED	75 mg	ORAL	ANDA	28 sections
bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2832	CAPSULE, LIQUID FILLED	75 mg	ORAL	ANDA	27 sections
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0285	CAPSULE	75 mg	ORAL	ANDA	28 sections
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	43975-315	CAPSULE, LIQUID FILLED	75 mg	ORAL	ANDA	27 sections
bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	68682-002	GEL	1 g	TOPICAL	NDA authorized generic	20 sections
bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	68682-003	CAPSULE, LIQUID FILLED	75 mg	ORAL	NDA authorized generic	25 sections
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1250	CAPSULE	75 mg	ORAL	ANDA	27 sections
Bexarotene	HUMAN PRESCRIPTION DRUG LABEL	1	69238-2088	GEL	10 mg	TOPICAL	ANDA	21 sections